Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Completed · Phase 3
Conditions studied: Breast Cancer
In brief
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane, letrozole, or anastrozole, may fight breast cancer by lowering the amount of estrogen the body makes. Giving exemestane, letrozole, or anastrozole before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether exemestane, letrozole, or anastrozole is more effective in treating breast cancer. PURPOSE: This randomized phase III trial is studying exemestane, letrozole, and anastrozole to compare how well they work in treating postmenopausal women who are undergoing surgery for stage II or stage III breast cancer.
Key facts
- Study ID
- NCT00265759
- Run by
- Alliance for Clinical Trials in Oncology
- People needed
- 622
- Starts
- 2006-01-01
- Expected to finish
- 2019-11-27
- Last updated by the study team
- 2025-04-23
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis — St Louis, Missouri, United States
- M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
- Doctor's Hospital of Laredo — Laredo, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.